ProShares UltraShort NASDAQ Biotechnology
7 hedge funds and large institutions have $938K invested in ProShares UltraShort NASDAQ Biotechnology in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.
1,768% more capital invested
Capital invested by funds: $50.2K → $938K (+$888K)
169% more call options, than puts
Call options by funds: $43K | Put options by funds: $16K
133% more funds holding
Funds holding: 3 → 7 (+4)
14.61% more ownership
Funds ownership: 0.8% → 15.41% (+15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$449K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$360K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$32.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$25.1K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$994 |
Top Sellers
BIS Hedge Fund Activity: Q1 2023 in Review
7 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2023, worth a combined $938K — up 1,768% from $50.2K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BIS positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $449K.
- 7 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2023, up from 3 in Q4 2022.
- Funds reported $938K of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2023, up 1,768% quarter-over-quarter.
- 4 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2023 and 0 closed out, a net change of +4 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2023 was Citadel Advisors, an estimated $449K added.
Based on aggregated 13F filings for Q1 2023.